Synonyms: JNJ 39758979 | JNJ39758979
Compound class:
Synthetic organic
Comment: JNJ-39758979 is a selective histamine H4 receptor antagonist [4] with anti-inflammatory potential.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Phase 2a clinical trial results in patients with moderate atopic dermatitis are published in [2] which indicate that the study did not meet its primary end-point, and produced drug-induced agranulocytosis, explaining its termination. Phase 2 trial NCT00946569 in asthma patients has been completed. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00946569 | A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma | Phase 2 Interventional | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |